In clinical studies, TREM2 is cleaved to myeloid soluble trigger receptor 2 (sTREM2) in plasma extracted from patients with ischemic stroke within 24 h, results of which suggest that early increase in sTREM2 levels is a predictor of poor outcome in stroke [91]. The gene discussed is TREM2; the disease is stroke disorder.